个人简介 Personal Profile 科研方向：1.卵巢癌耐药及免疫逃逸机制；肿瘤类器官在卵巢癌患者药物筛查、个性化用药及免疫治疗的临床转化应用；2.干细胞治疗卵巢早衰及宫腔粘连的临床前研究及转化应用。临床专业领域：1.卵巢囊肿、子宫肌瘤、子宫内膜异位症、不孕不育等妇科良恶性疾病的宫腹腔镜微创治疗、单孔腹腔镜手术治疗；2. 各种疑难妇科内分泌疾病的诊疗。学术任职：上海医学会妇科肿瘤学分会卵巢癌学组副组长中国医药教育协会生殖内分泌外科培训中心常务委员中国成人教育协会医学继续教育专业委员会腔镜国际培训中心委员中国抗癌协会肿瘤支持治疗专业委员会委员 研究方向Research Directions 妇科肿瘤学；生殖内分泌 2. 机电结构优化与控制 研究内容：在对机电结构进行分析和优化的基础上，运用控制理论进行结构参数的调整，使结构性能满足设计要求。1. 仿生结构材料拓扑优化设计, 仿生机械设计 研究内容：以仿生结构为研究对象，运用连续体结构拓扑优化设计理论和方法，对多相仿生结构(机构)材料进行2. 机电结构优化与控制 研究内容：在对机电结构进行分析和优化的基础上，运用控制理论进行结构参数的调整，使结构性能满足设计要求。1. 仿生结构材料拓扑优化设计, 仿生机械设计 研究内容：以仿生结构为研究对象，运用连续体结构拓扑优化设计理论和方法，对多相仿生结构(机构)材料进行整体布局设计。 整体布局设计。 团队展示 教育理念：热爱党的教育事业，以学生为主体，关注学生的进步以及发展，关注教学成果，以严谨求实为基调，积极把握学科动向，注重激发学生的兴趣并且培养学生的自主创新能力。教学实践：坚持因材施教，在带教过程中重视学生思维能力的培养，将临床知识进行系统化整体观综合分析，应用新的医学模式，带教时注重学生独立思考、分析问题的能力培养。同时，严格要求自己，加强自己的理论学习和师德修养，并且务实地进行师德实践。育人成效：目前指导8个研究生，其中6个为博士研究生，2个为硕士研究生。在课题策划、开展实施等多方面提供指导和意见，严格要求学生，尊重学生，使学生学有所得，从而不断提高自己的教学水平和思想觉悟，并顺利完成教育教学任务 项目情况 科研项目：1、上海市科学技术委员会医学创新研究专项项目，21Y11907000，基于深度学习和类器官模型建立子宫颈癌预后风险模型的临床研究，2021/10-2024/09，30万元，主持，在研。2、上海市自然科学基金项目，21ZR1450900，NAD+代谢介导STING通路增强卵巢癌CD8+T细胞抗肿瘤活性的机制研究，2021/07-2024/06，20万元，主持，在研。3、上海申康临床研究培育项目，SHDC12019X34，烟酸治疗卵巢早衰的临床研究，2019/11-2022/11，10万元，主持，在研。4、国家自然科学基金项目面上项目，81772762，lncRNA IL21-AS1经外泌体诱导肿瘤免疫逃逸微环境致卵巢癌铂类耐药的机制研究，2018/01-2021/12，57万元，主持，已结题。5、国家自然科学基金项目青年项目，81502227，miR-497双重靶向抑制Akt/mTOR/P70s6k信号通路逆转卵巢癌顺铂耐药的机制研究，2016/01-2018/12，19.2万元，主持，已结题。6、江苏省南京医科大学科技发展基金重点项目，2011NJMU2311，miR-200a、miR-141的DNA甲基化模式与卵巢癌的相关性研究，2012/01-2014/12，3万元，主持，已结题。7、 江苏省常州市卫生局重大科研项目，ZD201113，microRNA-200家族在卵巢癌中表达和作用机制的研究，2011/01-2013/12，15万元，主持，已结题。论文情况：1. Xu F, Zou C, Gao Y, Shen J, Liu T, He Q, Li S, Xu S*. Comprehensive Analyses Identify RIPOR2 as a Genomic Instability-Associated Immune Prognostic Biomarker in Cervical Cancer. Front Immunol.2022;2022:930488.2. Zou C, Xu F, Shen J, Xu S*. Identification of a Ferroptosis-Related Prognostic Gene PTGS2 Based on Risk Modeling and Immune Microenvironment of Early-Stage Cervical Cancer. J Oncol. 2022; 2022:3997562.3. Liu T, Shen J, He Q, Xu S*. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis. Frontiers in genetics. 2022; 13:814291.4. Shen J, Liu T, Lv J, Xu S*. Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer. Frontiers in cell and developmental biology. 2021; 9:746932.5. Xu F, Liu T, Zhou Z, Zou C, Xu S*. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Front Immunol. 2021; 12:749369.6. Shen J, Liu T, Bei Q, Xu S*. Comprehensive landscape of ovarian cancer immune microenvironment base on multi-omics integration analysis. Front Oncol. 2021; 11: 685065.7. Xu F, Shen J, Xu S*. Multi-omics Data Analyses Construct a Six Immune-Related Genes Prognostic Model for Cervical Cancer in Tumor Microenvironment. Front Genet. 2021; 12: 663617.8. Xu F, Shen J, Xu S*. Integrated Bioinformatical Analysis Identifies GIMAP4 as an Immune-Related Prognostic Biomarker Associated with Remodeling in Cervical Cancer Tumor Microenvironment. Front Cell Dev Biol. 2021; 9:637400.9. Dai Y, Cao Y, Kohler J, Lu A, Xu S*, Wang H*. Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes. BMC Genomics. 2021; 22(1):27.10. Li S#, Li Q#, Lu J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho William C, Xu S*, Yu Z*. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells. Front Genet. 2020; 10: 1278-1278.11. Tao Z#, Xu S#, Ruan H, Wang T, Song W, Qian L, Chen K*. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. Cell Physiol Biochem. 2018; 48(2):801-814.12. Xu S#, Tao Z#, Hai B, Liang H, Shi Y, Wang T, Song W, Chen Y, Ou Y, Chen J, Kong F, Dong Y, Jiang S, Li W, Wang P, Yuan Z, Wan X, Wang C, Li W, Zhang X, Chen K*. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016; 5(7):11406.13. Xu S#, Fu G#, Tao Z, Ou Y, Kong F, Jiang B, Wan X, Chen K*. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget. 2015; 28:26457-71.14. Xu S, Wang T, Song W, Jiang T, Zhang F, Yin Y, Jiang S, Wu K, Yu Z, Wang C, Chen K*. The inhibitory effects of AR/miR- 190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Sci Rep. 2015; 5:13528.15. Xu S, Xu P, Wu W, Ou Y, Xu J, Zhang G, Li J, Xu G*. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features. Curr Pharm Des. 2014; 20:1888–1895.16. Xu S, Ren J, Chen H, Wang Y, Liu Q, Zhang R, Jiang S, Li J*. Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells. Curr Pharm Des. 2014; 20(11):1881-7.17. Xu S, Wu W, Sun H, Lu J, Yuan B, Xia Y, Moor B, Marcha K, Wang X, Xu P, Cheng W*. Association of the Vascular Endothelial Growth Factor Gene Polymorphisms (–460C/T, +405G/C and +936T/C) with Endometriosis: A Meta-Analysis. Ann Hum Genet. 2012; 76:464-71. 科研项目 科研项目：1、上海市科学技术委员会医学创新研究专项项目，21Y11907000，基于深度学习和类器官模型建立子宫颈癌预后风险模型的临床研究，2021/10-2024/09，30万元，主持，在研。2、上海市自然科学基金项目，21ZR1450900，NAD+代谢介导STING通路增强卵巢癌CD8+T细胞抗肿瘤活性的机制研究，2021/07-2024/06，20万元，主持，在研。3、上海申康临床研究培育项目，SHDC12019X34，烟酸治疗卵巢早衰的临床研究，2019/11-2022/11，10万元，主持，在研。4、国家自然科学基金项目面上项目，81772762，lncRNAIL21-AS1经外泌体诱导肿瘤免疫逃逸微环境致卵巢癌铂类耐药的机制研究，2018/01-2021/12，57万元，主持，已结题。5、国家自然科学基金项目青年项目，81502227，miR-497双重靶向抑制Akt/mTOR/P70s6k信号通路逆转卵巢癌顺铂耐药的机制研究，2016/01-2018/12，19.2万元，主持，已结题。6、江苏省南京医科大学科技发展基金重点项目，2011NJMU2311，miR-200a、miR-141的DNA甲基化模式与卵巢癌的相关性研究，2012/01-2014/12，3万元，主持，已结题。7、 江苏省常州市卫生局重大科研项目，ZD201113，microRNA-200家族在卵巢癌中表达和作用机制的研究，2011/01-2013/12，15万元，主持，已结题。 研究成果 论文情况：1. Xu F, Zou C, Gao Y, Shen J, Liu T, He Q, Li S, Xu S*. Comprehensive Analyses Identify RIPOR2 as a Genomic Instability-Associated Immune Prognostic Biomarker in Cervical Cancer. Front Immunol.2022;2022:930488.2. Zou C, Xu F, Shen J, Xu S*. Identification of a Ferroptosis-Related Prognostic Gene PTGS2 Based on Risk Modeling and Immune Microenvironment of Early-Stage Cervical Cancer. J Oncol. 2022; 2022:3997562.3. Liu T, Shen J, He Q, Xu S*. Identification of a Novel Immune-Related lncRNA CTD-2288O8.1 Regulating Cisplatin Resistance in Ovarian Cancer Based on Integrated Analysis. Frontiers in genetics. 2022; 13:814291.4. Shen J, Liu T, Lv J, Xu S*. Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer. Frontiers in cell and developmental biology. 2021; 9:746932.5. Xu F, Liu T, Zhou Z, Zou C, Xu S*. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer. Front Immunol. 2021; 12:749369.6. Shen J, Liu T, Bei Q, Xu S*. Comprehensive landscape of ovarian cancer immune microenvironment base on multi-omics integration analysis. Front Oncol. 2021; 11: 685065.7. Xu F, Shen J, Xu S*. Multi-omics Data Analyses Construct a Six Immune-Related Genes Prognostic Model for Cervical Cancer in Tumor Microenvironment. Front Genet. 2021; 12: 663617.8. Xu F, Shen J, Xu S*. Integrated Bioinformatical Analysis Identifies GIMAP4 as an Immune-Related Prognostic Biomarker Associated with Remodeling in Cervical Cancer Tumor Microenvironment. Front Cell Dev Biol. 2021; 9:637400.9. Dai Y, Cao Y, Kohler J, Lu A, Xu S*, Wang H*. Unbiased RNA-Seq-driven identification and validation of reference genes for quantitative RT-PCR analyses of pooled cancer exosomes. BMC Genomics. 2021; 22(1):27.10. Li S#, Li Q#, Lu J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho William C, Xu S*, Yu Z*. Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells. Front Genet. 2020; 10: 1278-1278.11. Tao Z#, Xu S#, Ruan H, Wang T, Song W, Qian L, Chen K*. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. Cell Physiol Biochem. 2018; 48(2):801-814.12. Xu S#, Tao Z#, Hai B, Liang H, Shi Y, Wang T, Song W, Chen Y, Ou Y, Chen J, Kong F, Dong Y, Jiang S, Li W, Wang P, Yuan Z, Wan X, Wang C, Li W, Zhang X, Chen K*. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016; 5(7):11406.13. Xu S#, Fu G#, Tao Z, Ou Y, Kong F, Jiang B, Wan X, Chen K*. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget. 2015; 28:26457-71.14. Xu S, Wang T, Song W, Jiang T, Zhang F, Yin Y, Jiang S, Wu K, Yu Z, Wang C, Chen K*. The inhibitory effects of AR/miR- 190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. Sci Rep. 2015; 5:13528.15. Xu S, Xu P, Wu W, Ou Y, Xu J, Zhang G, Li J, Xu G*. The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features. Curr Pharm Des. 2014; 20:1888–1895.16. Xu S, Ren J, Chen H, Wang Y, Liu Q, Zhang R, Jiang S, Li J*. Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells. Curr Pharm Des. 2014; 20(11):1881-7.17. Xu S, Wu W, Sun H, Lu J, Yuan B, Xia Y, Moor B, Marcha K, Wang X, Xu P, Cheng W*. Association of the Vascular Endothelial Growth Factor Gene Polymorphisms (–460C/T, +405G/C and +936T/C) with Endometriosis: A Meta-Analysis. Ann Hum Genet. 2012; 76:464-71. 学生信息 当前位置：教师主页 > 学生信息 入学日期 所学专业 学号 学位 招生信息 当前位置：教师主页 > 招生信息 招生学院 招生专业 研究方向 招生人数 推免人数 考试方式 招生类别 招生年份
